My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    U-104
    U-104

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0895
    CAS #: 178606-66-1Purity ≥98%

    Description: U-104 (also known as MST-104, SLC-0111 and NSC 213841) is a novel and potent inhibitor of transmembrane carbonic anhydrase (CA) with Ki of 45.1 nM and 4.5 nM for CA IX and CA XII, respectively, it has very low inhibition for CA I and CA II. Tumor volume measurements show important inhibition of primary tumor growth in the mice treated with the U-104 compound compared with vehicle controls. It also has ability to inhibit metastasis formation in the 4T1 experimental metastasis model. 

    References: Cancer Res. 2011 May 1;71(9):3364-76; Oncogene. 2013 Oct 31;32(44):5210-9.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)309.32
    FormulaC13H12FN3O3S
    CAS No.178606-66-1
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 62 mg/mL (200.4 mM)
    Water: < 1 mg/mL
    Ethanol: < 1 mg/mL
    Solubility (In vivo)30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL
    SynonymsMST-104, SLC0111; SLC 0111; U-104; NSC 213841; MST104;  MST 104; NSC-213841; NSC213841; SLC-0111; U104; U 104.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: U-104 (50  μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50  μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. U-104 possesses aromatic groups at the second nitrogen ureido group.


    Cell Assay: U-104 (50 μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells.

    In VivoU-104 (38 mg/kg) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. U-104 (19 mg/kg) inhibits metastases formation in the 4T1 experimental metastasis mice model. U-104 (38 mg/kg) significantly delay primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells. U-104 (5 mg/mL, oral gavage) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells.
    Animal modelBalb/c mice orthotopically implanted with 4T1 cells.
    Formulation & DosageDissolved in 55.6% PEG 400, 11.1% ethanol and 33% water; 5 mg/kg; oral gavage
    ReferencesCancer Res. 2011 May 1;71(9):3364-76; Oncogene. 2013 Oct 31;32(44):5210-9.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    U-104

    The metastatic 4T1 primary tumor is a valid preclinical model of hypoxia-induced CAIX expression. Cancer Res. 2011 May 1;71(9):3364-76. 
     

    U-104

    Silencing CAIX expression in metastatic 4T1 cells inhibits cell survival and alters pHe in hypoxia. Cancer Res. 2011 May 1;71(9):3364-76.  
     

    U-104

    Growth of primary breast tumors characterized by hypoxia requires the expression of CAIX. Cancer Res. 2011 May 1;71(9):3364-76. 
     

    U-104

    Inhibition of CAIX expression or activity attenuates metastasis of 4T1 mouse mammary tumors. Cancer Res. 2011 May 1;71(9):3364-76. 
     

    U-104

    Targeting CAIX activity with selective small molecule inhibitors of CAIX attenuates the growth of mouse and human breast tumors. Cancer Res. 2011 May 1;71(9):3364-76. 
     

    U-104

    Novel selective small molecule inhibitors of CAIX inhibit metastasis formation by 4T1 mammary tumor cells. Cancer Res. 2011 May 1;71(9):3364-76. 


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?